Two therapies can be better than one for treating some cancers, concludes a Yale study published Oct. 22 in JCI Insight that ...
BCG failure is much less common than previously thought in non-muscle invasive bladder cancer, so is adding a checkpoint ...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing ...
A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...
MAIA also announced that it has enrolled five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 trial. Screening for the trial is ongoing in Europe and Asia. With ...
The COVID-19 mRNA-based vaccines that saved 2.5 million lives globally during the pandemic could help spark the immune system ...
Getting a COVID shot might do more than protect against the virus – it could also help cancer patients live longer. A new ...
RNA-based COVID vaccines may enhance the immune response to certain cancer treatments. Advanced lung and skin cancer patients ...
Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. Genmab and BioNTech SE are ...
Vietnam Investment Review on MSN
China fast tracks Gotistobart as breakthrough cancer drug
OncoC4 announced today that China's National Medical Product Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for gotistobart (BNT316/ONC392) for the treatment of patients with ...
A study presented at the annual European Society of Medical Oncology Congress 2025 and published in the journal Annals of ...
Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback